3D tumor models
Human tumor architecture for stronger clinical relevance
To truly understand how cancer therapeutics will behave in patients, developers need to go straight to the source. But testing done in the drug discovery phase cannot easily replicate this. That is why our organ-specific, in vitro models were designed to better mimic the physiological environment of human tissue. Armed with clinically representative data, developers can make better-informed decisions, sooner.
zPREDICTA is now Predictive Oncology.
Increasing relevance, improving outcomes
What can 3D tumor models do for you?
Bringing the human element into early drug discovery can help greatly bolster success during clinical trials. Our unique multi-component, organ-specific extracellular matrix (ECM) enables that—because it accurately reconstructs human tissue architecture for more accurate predictions of clinical outcomes. By testing drug candidates via a more clinically representative method, we optimize candidate screening, evaluation of off-target toxicity and biomarker discovery—all to boost the odds of ultimate success in clinical trials.
Shelved drugs could hold strong promise in the fight against cancer—but identifying opportunities with a high degree of confidence can be challenging. With patient-derived 3D tumor models, you will get pre-clinical data that is more representative of what you may see in patients during clinical trials—so you can move forward with a higher degree of confidence.
- Screen therapeutics and drug combinations (small molecules, antibodies, biologics)
- Evaluate immuno-oncology agents (antibody-drug conjugates (ADC), bi/tri-specifics, CAR-T cells)
- Ascertain bystander effect and remodeling of tumor microenvironment
- Discover new targets in primary and metastatic tumors
- Determine mechanism(s) of action and immune-regulation
Talk to us about 3D tumor models today.
Complete the form and we’ll be in touch to discuss customized solutions for your needs.